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ABSTRACT
Objective: To study the feasibility of multimodal
neuroimaging in mild to moderate Alzheimer disease (AD)
and to estimate the size of possible treatment effects of
memantine on potential functional, structural and meta-
bolic biomarkers of disease progression.
Methods: In this randomised, double-blind, placebo-
controlled pilot study, 36 patients with moderate AD
received 52 weeks of memantine (20 mg/day) or
placebo. Patients were re-evaluated after 26 and
52 weeks to measure the change from baseline in several
outcome measures including global and regional glucose
metabolism, total brain and hippocampal volumes, as well
as chemical shift imaging-derived global and regional
N-acetylaspartate and myoinositol concentrations.
Results: In the total population, global glucose metabo-
lism decreased by 2.3% (p,0.01), total brain volume by
2.1% (p,0.001) and hippocampal volume by 2.7%
(p,0.01) after 52 weeks. Chemical shift imaging (CSI)
spectra were severely affected by patient-induced
artefacts and highly variable. Patients receiving meman-
tine showed less decline in glucose metabolism in all brain
areas than patients on placebo. Their loss of hippocampal
volume was substantially smaller (2.4% vs 4.0%). No
between-group differences were seen for changes in total
brain volume.
Conclusions: The results support the use of multimodal
imaging including MRI and positron emission tomography
(PET) to monitor the progression of moderate AD. CSI
yielded unreliable longitudinal results. The data suggest
that memantine has potentially protective effects in AD
and they can be used for planning larger confirmatory
studies on the cerebral effects of memantine.
Current treatments in Alzheimer disease (AD)
apparently do not slow the disease.
1 Therapies
that modify AD by interfering with the underlying
neurodegeneration are under investigation.
2
Neuroimaging markers that substantiate disease-
modifying effects are attractive investigational
targets.
34The rate of whole brain and hippocampal
volume loss, longitudinal changes in N-acetylas-
partate (NAA), choline and myoinositol (MI)
concentrations, and decline in brain perfusion and
metabolism, are potential imaging endpoints for
therapeutic trials.
4 They reportedly correlate with
the severity of histopathology
5–8 and cognitive
performance.
4
Few therapeutic trials have implemented these
measures in patients with AD and most of them
used a single modality approach.
9–14 This provides a
restricted view on disease-related changes over
time and considers only selected aspects of treat-
ment effects although these may be manifold,
including brain metabolism, function and struc-
ture. These different aspects may now be appre-
ciated by specific imaging technologies, but the
feasibility and contribution of long-term multi-
modal imaging to study therapeutic responses in
AD has not yet been sufficiently explored.
Knowledge of long-term change in different
imaging measures and assessment of the variability
of results in patients with AD are a prerequisite for
the use of such methods in treatment trials, as is
reproducibility assessment. Such data could be
obtained from a purely observational study
unclouded by possible therapeutic effects.
However, it is difficult to conduct long-term
studies in patients with AD without offering them
any treatment. We therefore performed a 1-year
pilot feasibility study on multimodal imaging in
mild to moderate AD coupled with specific
treatment. We determined the longitudinal
changes and their variability on
18F-fluorodeoxy-
glucose (FDG) positron emission tomography
(PET), chemical shift imaging (CSI) and 3D MRI
in patients with AD who had been randomised to
receive either memantine or placebo.
PATIENTS AND METHODS
Patients
Patients over 50 years old were eligible if they had a
diagnosis of probable AD according to the
Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV
15 and National Institute of
Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS–ADRDA) cri-
teria,
16 a Hachinski score (4,
17 and an Mini-
Mental State Examination (MMSE) score between
14 and 22.
18 When we started the study, cholines-
terase inhibitors were approved in Austria for mild
to moderate AD (MMSE 12–24), and memantine
for moderately severe and severe AD (MMSE
3–14). We considered a placebo group to be crucial
but did not want to exclude study participants
from approved treatments. Therefore, we included
only those patients who (1) had either failed to
respond to cholinesterase inhibitors or experienced
severe side effects leading to termination of such
treatment and (2) had MMSE scores .14, which,
at the time of study conduct, had excluded them
from other approved antidementia treatment once
cholinesterase inhibitors had been stopped. To
avoid withholding licensed therapy from study
participants, we a priori defined that, whenever a
participant worsened clinically obtaining an
MMSE score ,15, he/she would be switched
to active treatment without breaking the
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cases in the placebo group.
None of the patients included could obtain licensed treatment
at study entry or would be withheld such treatment during the
study, which prompted the local ethics committee to approve a
1-year placebo-controlled trial. Cholinesterase inhibitor treat-
ment had to be terminated at least 4 weeks before screening. In
addition, patients had to be in generally good health,
ambulatory and with sufficient hearing and vision for com-
pliance with testing procedures. Only patients able to undergo
MRI were enrolled. Patients with a primary diagnosis of
psychiatric disorders other than AD, cerebrovascular disease,
or any unstable medical condition were excluded. Patients were
permitted to continue on stable doses of concomitant medica-
tions received at least 3 months before screening. These
included low-dose atypical neuroleptics, selective serotonin re-
uptake inhibitors, non-centrally active antihypertensives, anti-
inflammatory drugs, platelet antiaggregants and anticoagulants,
laxatives, diuretics and sedatives/hypnotics. Anticonvulsants,
anti-Parkinson agents, barbiturates, Gingko biloba and nootro-
pics, systemic corticosteroids and insulin were not permitted.
The study was carried out according to the Declaration of
Helsinki. Written informed consent was obtained from the
patients and their caregivers.
Protocol
This was a single-centre, 52-week, randomised, double-blind,
placebo-controlled, parallel-group pilot study conducted at the
Medical University of Graz, Graz, Austria, between March 2003
and August 2005. Patients were randomly assigned by a
computerised randomisation schedule to either placebo or
memantine. Randomisation used a permuted block design and
considered the presence or absence of an apolipoprotein-E-e4
allele as a stratification criterion, because of previous data
indicating more rapid decline in apolipoprotein-E-e4 carriers.
19
Briefly, two randomisation lists were generated, one for all
patients carrying at least one apolipoprotein-E-e4 allele and one
for all other apolipoprotein-E genotypes, so that carriers and
non-carriers were equally distributed between the two treat-
ment groups.
Patients assigned to memantine were titrated to a dose of
20 mg/day over a 4-week period. Daily dose consisted of two
identical tablets so as not to reveal the titration scheme: two
placebo tablets throughout the study for patients treated with
placebo and two tablets containing either 5 mg or 10 mg
memantine depending on the titration stage for patients treated
with memantine. Evaluation of imaging data was performed
blinded to the patients’ clinical results.
We screened patients by medical history, physical and
neuropsychiatric examination, laboratory assessment including
apolipoprotein-E genotyping, MMSE,
18 Geriatric Depression
Scale (GDS),
20 and modified Hachinski scale.
17 All subjects had
an electrocardiogram (ECG) and a brain computed tomography
(CT) or MRI scan not older than 1 year. Screening was
performed within 31 days before patients began double-blind
treatment and verification of AD diagnosis was based on
screening results. At baseline, we repeated the physical
examination including vital signs, MMSE and laboratory tests.
In addition, participants underwent psychometric testing
including Alzheimer Disease Assessment Scale – cognitive
subscale (ADAS-Cog),
21 Clinical Dementia Rating (CDR),
22
and Alzheimer Disease Cooperative Study – activities of daily
living (ADCS-ADL) inventory ,
23 and MRI, quantitative
1H-CSI
and
18F-FDG PET. The first dose of study medication was then
administered. Follow-up visits were scheduled at the end of
weeks 12, 26 and 52. At each follow-up visit, routine physical
examination, laboratory tests, psychometric testing, medication
compliance check and adverse events monitoring were per-
formed.
MRI and
1H-CSI were repeated at weeks 26 and 52; PET
scanning was repeated at the end of week 52, only. Patients
who withdrew prematurely were requested to return for a final
evaluation identical to week 52.
Efficacy assessments
The outcome variables were changes of total brain and
hippocampal volume, regional changes in NAA and MI in
relation to baseline at weeks 26 and 52, as well as the global and
regional changes of glucose metabolism between baseline and
week 52.
18F–FDG Positron Emission Tomography (PET)
PET scans were acquired on a Siemens-ECAT scanner (Siemens
Medical Systems, Erlangen, Germany) 30 min after intravenous
injection of 250 MBq of
18F-FDG. Imaging was performed in a
resting condition with eyes open and ears unoccluded in a dark
room with minimal ambient noise. Transmission scans were
acquired before the emission scan for attenuation correction.
The imaging plane was parallel to the canthomeatal line. The
spatial inplane resolution was 4.5 mm and axial resolution was
6 mm full width at half maximum. Using a filtered back-
projection method, all images were reconstructed in a
1286128663 matrix providing a pixel size of 2.562.562.4 mm.
MRI
The acquisition of structural scans and CSI was performed in a
single session on a 1.5T Philips-Intera scanner (Philips Medical
Systems, Best, The Netherlands). The scan protocol included an
axial fluid-attenuated inversion recovery (FLAIR) sequence
(repetition time (TR)=6000 ms; echo time (TE)=130 ms;
inversion time (TI)=1200 ms; field of view (FOV)=230 mm;
matrix=2566256; slice thickness (THK)=5 mm), an axial T2-
weighted fast spin echo (FSE) sequence (TR=3900 ms;
TE=80 ms; FOV=230 mm; matrix=2566256;
THK=5 mm) and a volumetric magnetisation-prepared rapid
acquisition gradient echo (MPRAGE) sequence (flip angle=15u;
TR=20 ms; TE=4.5 ms; TI=400 ms) with whole brain
coverage. To allow manual segmentation of the hippocampus,
the MPRAGE sequence was acquired perpendicularly to the long
axis of the hippocampus with a 1.061.0 mm inplane resolution
and with 1.2 mm-thick partitions. Additionally, for the CSF
correction of the CSI data and for the regional analysis of the
PET data, a T1-weighted true inversion recovery (IR)-FSE
sequence (TR=4400 ms; TE=15 ms; TI=350 ms) with a
high inplane resolution (0.4560.90 mm) was performed in an
axial orientation.
Quantitative
1H-CSI
CSI was performed in a single axial slice using a point-resolved
spectroscopy sequence (PRESS) and a circularly polarised
transmit-receive coil. The PRESS sequence was performed with
TE=30 ms, TR=1500 ms and a 24624 acquisition matrix.
The 15 mm-thick slice had an inplane resolution of 10610 mm
and was positioned to match exactly the five central slices of the
IR-FSE sequence. The PRESS sequence was performed slice-
selectively instead of selecting a large volume of interest. This
enabled full coverage of the parenchyma in the imaging slice but
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from bone and skull. Water suppression was performed with an
adiabatic saturation pulse. Shimming and power optimisation
was performed fully automated. To allow for eddy current
correction and improved phasing of the spectra, a water-
unsuppressed reference scan with a reduced acquisition matrix
(12612) but otherwise identical parameters was performed
prior to the water-suppressed scan. To obtain absolute
metabolite concentrations, a calibration measurement with a
spherical phantom containing 50 mmol/litre NAA and
100 mmol/litre phosphate was performed after each session.
To correct for variation of the coil load between patients and
the calibration phantom, the coil load for each measurement
was determined during the power optimisation process and
recorded. The acquisition time for MRI and CSI without
calibration was approximately 45 min.
Analysis of imaging data
Glucose metabolism
Regional glucose metabolism was measured manually in pre-
defined regions ofinterestinthe PET imagesincluding the frontal,
parietal, occipital and temporal lobe, and the basal ganglia. The
relative counts obtained from these regions were normalised by
the pons activity. Region outlining was performed on the baseline
IR-FSE scan, after the baseline and follow-up PET scan had been
registered with it. Registration was performed with an affine
nine-parameter model following skull stripping of the IR-FSE
scan.
24 The region masks produced at baseline were also used for
the analysis of the follow-up PET scans.
Brain volumes
Whole brain atrophy and normalised brain volume (NBV) were
calculated from the MPRAGE scan using the fully automated
structural image evaluation, using normalisation, of atrophy
(SIENA) and structural image evaluation, using normalisation,
of atrophy (cross sectional) (SIENAX) methods, respectively,
which are part of the University of Oxford Functional MRI of
the Brain (FMRIB) group’s Software Library (FSL) (http://
www.fmrib.ox.ac.uk/fsl).
25 In addition to its robustness, SIENA
provides an error in brain volume change of about 0.2%.
26
SIENAX determines NBV by extraction of brain tissue,
calculation of brain volume and normalisation for subject head
size using a volumetric scaling factor. The scaling factor is
obtained by an affine registration of the brain image to MNI152
space. The NBV was assessed at baseline only, while the
measurement of brain volume change was performed for all
subsequent time points. Hippocampal volumes were measured
from the T1-weighted MPRAGE scans. After image intensity
normalisation and registration with the baseline examination,
manual tracing of the hippocampal formation was performed
on magnified and interpolated coronal sections. Manual tracing
was performed blinded to clinical information and time point of
examination, in consultation with neuroanatomic atlases.
26 27
The outlined volume included the hippocampus proper (cornu
ammonis CA1 through CA4), gyrus dentatus, subiculum, uncal
apex, fimbria and alveus, and excluded the entorhinal cortex
(ambient gyrus, parahippocampal gyrus).
72 8The hippocampal
volume was obtained by averaging the volume of the left and
the right hippocampus.
Brain metabolites
CSI data were processed voxel by voxel by the fully automated
method LCModel.
29 LCModel analyses an in vivo spectrum as a
linear combination of model spectra of metabolite solutions in
vitro and provides absolute quantification by reference to an
external calibration standard. To account for differences in
scanner characteristics between the acquisition of the metabo-
lite solutions in vitro and the in vivo spectra, LCModel uses a
calibration factor to scale the in vivo spectra. According to the
methodological requirements, the calibration factor was
obtained by using LCModel to estimate the known NAA
concentration in the calibration phantom and by regarding
differences in the coil load factor. Additionally, the low-
resolution, unsuppressed CSI data were incorporated in the
algorithm to facilitate phasing and eddy-current correction.
NAA and MI maps showing the absolute metabolite concentra-
tions were generated from the voxel-wise analysis. These maps
were then overlaid on the central slices of the IR-FSE scan,
which were virtually aligned with the CSI data. No active
registration of the IR-FSE scan and metabolite maps was
performed. Regional measurement of metabolite concentration
was performed by clustering individual voxels using bespoke in-
house tools. Due to the high resolution and excellent T1
contrast, the IR-FSE scan also allowed to separate grey matter,
white matter and CSF in each spectroscopic voxel to correct for
CSF occupancy. The relative CSF occupancy was calculated by
fitting three Gaussian functions into the signal intensity
distribution function in each voxel.
Statistical analyses
This study was a first attempt to provide morphological and
functional imaging data on the action of memantine in AD in a
complex multimodal manner, and was thus designed as a pilot
study. All efficacy variables were analysed in a descriptive and
exploratory manner. p Values have to be interpreted accord-
ingly, with no adjustments made for multiplicity. The analyses
were performed by intention-to-treat. Differences in percentage
brain volume change and annual change of normalised glucose
metabolism for the whole brain and predefined brain regions
between the two groups were assessed using the unpaired
Student t test or Mann–Whitney U test, as appropriate.
Analysis was performed for changes from baseline to 6 and
12 months. A paired Student t test or the Wilcoxon signed rank
test was used for the difference between baseline and final
examination overall and within groups. For NAA or MI levels
within regions of interest, analysis of covariance including
treatment group as the main factor in the model and baseline as
covariate was performed. The correlation between glucose
metabolism and volumetric measures was determined with
the Spearman rank correlation coefficient.
RESULTS
A total of 37 patients were randomised, of which 36 (1 had
claustrophobia in the MRI scanner) received study medication
(18 memantine and 18 placebo). Baseline characteristics of the
study group are shown in Table 1. The two groups were
comparable regarding age, gender, depression score, severity of
cognitive symptoms and normalised brain volume.
The 26-week follow-up was completed by 32 (89%) patients
(16 in each group); 24 (67%) participants (11 on placebo and 13
on memantine) finished the 52-week examination. Overall, 12
(7 placebo and 5 memantine) patients (33.3%) discontinued the
study due to adverse events in 4, implantation of pacemaker in 3,
technical MRI problems in 2 and non-compliance in 2 subjects.
One patient died prior to the 52-week examination. All patients
on memantine and 94% of patients on placebo received
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memantine group, 33% and 28% received low-dose neuroleptics,
respectively; antidepressants were used in 39% and sedatives/
hypnotics in 11% of patients in each group. Clinically, the total
group was stable until week 26 and declined in all clinical
assessments at week 52 (4.2 points on ADAS-Cog, 1.3 on MMSE,
0.4 on CDR and 11 on ADCS-ADL). The 52-week decline in
patients on placebo on the ADAS-Cog, MMSE, CDR and ADCS-
ADL was 8.2, 2.0, 0.5 and 5.1 points, respectively. With 1.0, 0.7,
0.3 and 5.1 points, the clinical 52-week decline in study
participants treated with memantine was slower.
After 52 weeks, the mean (SD) global decrease in cerebral
glucose metabolism from baseline was 2.3% (4.96%); p,0.01.
Significant regional metabolic reductions were seen in the
parietal (3.1% (5.20%)), basal ganglionic (2.7% (6.00%)) and
temporal (2.3% (4.01%)) brain areas (p,0.01 each). Declines in
the frontal (2.1% (5.96%)) and occipital (1.3% (5.50%)) areas
were non-significant. Longitudinal coregistration of baseline
and 52-week follow-up PET studies on MRI reference scans
depicted the distribution of functional loss over time. Most
AD cases showed a diffuse glucose metabolism decrease
involving all brain areas, but some developed substantial
asymmetric and focally confined reductions in brain metabo-
lism over time (fig 1 A, B). Memantine-treated subjects
showed less annual decline in glucose metabolism in all brain
areas compared to placebo (fig 2). The differences were non-
significant. In relative terms, the annual decline in global
glucose metabolism in patients on memantine was 41%
smaller than in those on placebo.
Table 2 shows the changes of MRI volumetric endpoints over
time. There was a significant loss of total brain (2.1% per year;
p,0.001) and hippocampal (2.7% per year; p,0.01) volumes in
all patients. The annual reduction in total brain volume was
similar between the groups (2.0% placebo vs 2.3% memantine).
At study end, patients on memantine showed 40.6% less
hippocampal volume reduction than patients on placebo (2.4%
vs 4.0%).
There existed no significant relationship between global
change in glucose metabolism and percentage change in total
brain (r=20.02) and hippocampal (r=20.28) volume. Even in
the case with almost complete regional drop in glucose
metabolism, only minimal sulcal widening was seen at the
affected site during the 52-week observational period (fig 1C,D).
CSI was severely affected by patient-induced artefacts,
mostly due to patient motion during the 20-min acquisition
time. Motion resulted in incomplete fat saturation and marked
line-width broadening in most cases. Depending on the brain
region, many spectra were excluded from analysis due to
unacceptable quality; this decision was made before unblinding.
The exclusion rate was lowest in the parietal (5 cases) and
highest in the occipital (19 cases) brain area. Analysis of the
remaining spectra still yielded a high intra and interindividual
variability of all metabolites with no clear trends over time for
the entire cohort and patient subgroups (data not shown).
DISCUSSION
We have demonstrated that multimodal functional and
morphological neuroimaging is feasible in a treatment trial of
patients with moderate AD. This 52-week study yielded
significant reductions in glucose metabolism and total brain
and hippocampal volumes in a group of patients with AD with
significant clinical deterioration. Our patients on placebo
showed similar cognitive decline to that reported in large-scale
clinical AD trials,
30 and their annual 2.0% loss of total brain
volume and 4.0% loss of hippocampal volume are also
Table 1 Baseline characteristics of patients with Alzheimer disease
(AD) in a 52-week, randomised, double-blind, placebo-controlled trial on
the effects of memantine on brain morphology and metabolism
Characteristic
Total group
(n=36)
Placebo
(n=18)
Memantine
(n=18)
Age, years 76.2 (5.21) 75.8 (5.70) 76.5 (4.81)
Sex, female 23.0 (63.9) 10.0 (55.6) 13.0 (72.2)
Apolipoprotein-E-e4 allele 16.0 (44.4) 8.0 (44.4) 8.0 (44.4)
Hachinski score 1.1 (1.27) 0.8 (0.99) 1.4 (1.46)
MMSE 19.0 (2.90) 19.3 (2.72) 18.7 (3.12)
GDS 2.4 (0.94) 2.2 (1.00) 2.6 (0.85)
CDR 1.6 (0.56) 1.5 (0.51) 1.6 (0.61)
ADAS-Cog 27.5 (10.59) 27.5 (10.00) 27.6 (11.45)
Normalised brain volume, ml 1298.3 (76.5) 1311.4 (77.5) 1285.9 (75.8)
All data are expressed as mean and standard deviation (SD) except for sex and APO-E-
e4 allele, which are expressed as frequency and percentage.
ADAS-Cog, Alzheimer Disease Assessment Scale – cognitive subscale; CDR, Clinical
Dementia Rating; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State
Examination.
Figure 1 A–D. Baseline (A) and 52-week (B) positron emission
tomography (PET) scans registered on MRI in an 85-year-old female
study participant who experienced a focal, almost complete loss of
glucose utilisation in the right temporoparietal region. Glucose
metabolism in other brain regions remained almost unchanged from
baseline. The baseline scan demonstrated the typical symmetric
temporo-parietal hypometabolism of patients with Alzheimer disease
(AD). The coregistered T1-weighted MRI scans show little, if any, sulcal
enlargement in the area of metabolic loss in this patient between
baseline (C) and follow-up (D).
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31–34 which supports the validity
of our study.
The greatest problems were posed by CSI. It is important to
note here that there was a tremendous difference between
single-voxel MRS and CSI regarding motion sensitivity.
Obviously, a 20-min acquisition time required per our quanti-
tative CSI protocol was too long for many study participants. In
patients who remained still in the scanner, CSI was technically
feasible, but data quality was often severely degraded by
patient-induced motion artefacts. Typically, head motion
resulted in line-width broadening and displacement errors
leading to a high rate of spectra of unacceptable quality and
to highly variable metabolite concentrations. Thus, low patient
compliance can clearly be a major limiting factor when using
CSI in longitudinal dementia studies.
Recent developments such as turbo CSI or the incorporation
of the SENSE technique reduces acquisition time and may
overcome some of the problems we encountered. Until
respective studies are available, single-voxel spectroscopy with
substantially shorter acquisition times may be preferable in
demented patient populations.
We saw no, or at most poor, correlations between metabolic
and volumetric cerebral changes over time. Even in the case
with almost complete focal loss of metabolic activity in the
right temporal-parietal area, sulcul widening was barely present.
This suggests long-term latency between functional deteriora-
tion and cellular loss in AD, a finding corroborated by studies in
presymptomatic familial AD individuals who also showed
widespread reductions in glucose metabolism in the relative
absence of structural brain changes long before the clinical onset
of the disease.
35
This is also the first investigation utilising neuroimaging
techniques to study treatment effects of memantine.
Memantine preferentially blocks excessive N-methyl-D-aspartic
acid (NMDA) receptor activity without disrupting normal
receptor activity and is thought to be a neuroprotective agent
that attenuates excitotoxicity. Various experiments on cellular
and tissue level as well as in animal models support this
assumption.
36 Selection of imaging methods for the current
study attempted to cover possible treatment-related effects as
comprehensively as possible. Slowing of decline in glucose
metabolism and of hippocampal volume loss seen in patients
treated with memantine compared to those on placebo is in
favour of functional and neuroprotective effects of this
substance. However, caution is advised when interpreting these
findings, because our study was not powered to detect
statistically significant results and we could be dealing with
spurious findings. It is important to emphasise that this study
was conducted to facilitate planning of larger confirmatory
trials. Nevertheless, glucose metabolism in patients treated with
memantine was preserved longer in all brain areas, and the
effects on PET results and on hippocampal volume were
substantial (PET global annual change: 1.8% in patients treated
with memantine vs 3% in patients on placebo; hippocampal
volume annual percentage change: 2.4% in patients treated with
memantine vs 4% in patients on placebo). In relative terms,
global cerebral glucose utilisation and hippocampal volume
showed a non-significant trend towards a 40% lower annual
decline in the memantine than in the placebo group. This result
can serve for rough orientation on sample sizes needed. Based on
memantine’s 1-year effect on global glucose metabolism and
hippocampal volume, the sample sizes required to detect this
40%-reduction in a 1-year trial with a power of 80% (two-sided
Student t test at 5% level) are 202 and 70 patients per group,
respectively.
The use of multimodal imaging in this study suggests that
memantine has functional effects in all brain regions affected by
AD while the substance exerted morphological effects only on
the hippocampus but not on the whole brain. We certainly
cannot exclude that global effects on brain volume may be seen
with observation times exceeding 1 year. Hypotheses explaining
slower hippocampal degeneration in the absence of effects on
total brain volume are difficult to formulate as the mechanisms
of neuronal loss in AD are largely unknown. Possibly, the
hippocampus may be particularly involved in mild to moderate
AD stages studied in the current trial. Another explanation is
that memantine exerts more pronounced activity on the
hippocampus than on other brain regions because the hippo-
campus contains a high density of NMDA receptors, particu-
larly in the CA1 area.
In conclusion, the data of this pilot study show that
multimodal neuroimaging is feasible in a patient population
with mild to moderate AD, and consistent changes over time
Figure 2 Regional and global changes from baseline in glucose
metabolism in patients with Alzheimer disease in a 52-week randomised,
double-blind, placebo-controlled trial. Numbers below regions indicate
the percentage decline in patients receiving memantine vs those
receiving placebo. After 52 weeks, memantine-treated subjects had
smaller reductions in all brain regions and globally. Differences did not
reach statistical significance in this pilot study.
Table 2 Changes in MRI volumetric outcome measures from baseline in patients with Alzheimer disease (AD) in a 52-week, randomised, double-blind,
placebo-controlled trial of the effects of memantine on brain morphology and metabolism
Imaging endpoint Assessment n Total group n Placebo n Memantine
Volumetry Brain volume change (%) Week 26 29 20.6 (1.69) 15 20.8 (2.04) 14 20.6 (1.23)
Week 52 21 22.1 (2.01) 12 22.0 (1.92) 9 22.3 (2.22)
Hippocampal volume change
(%)
Week 26 29 21.9 (2.82) 15 22.4 (2.01) 14 22.0 (2.70)
Week 52 21 22.7 (3.64) 12 24.0 (3.99) 9 22.4 (2.81)
Numbers are mean (SD). Differences between treatment groups were non-significant based on analysis of covariance (ANCOVA).
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that memantine slows the decline in glucose metabolism and
slows the progression of hippocampal atrophy supporting its
potential disease-modifying effect in AD. Larger trials including
PET scanning and hippocampal measurements are warranted to
confirm these results.
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